Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2009
11/05/2009WO2009134718A1 Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
11/05/2009WO2009134658A2 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
11/05/2009WO2009134574A2 Disubstituted phthalazine hedgehog pathway antagonists
11/05/2009WO2009134443A2 Rna-induced translational silencing and cellular apoptosis
11/05/2009WO2009134428A2 Methods and compositions for modulating angiogenesis and pericyte composition
11/05/2009WO2009134396A2 Methods of using corticotropin-releasing factor for the treatment of cancer
11/05/2009WO2009134204A1 RESTORATION OF ESTROGEN RECEPTOR-α ACTIVITY
11/05/2009WO2009133963A1 Methods of administering antitumor agent comprising deoxycytidine derivative
11/05/2009WO2009133905A1 Peptide capable of inhibiting activity of human fibroblast growth factor-23 (human fgf-23), and pharmaceutical composition comprising the same
11/05/2009WO2009133863A1 Immunopotentiating agent comprising ep1 agonist
11/05/2009WO2009133831A1 Phenylpropionic acid derivative and use thereof
11/05/2009WO2009133545A2 Vascular delivery systems
11/05/2009WO2009133220A1 Gene e for antitumour treatment
11/05/2009WO2009133147A1 Novel triazole derivatives, their preparation and their application in therapeutics
11/05/2009WO2009133136A1 Compounds
11/05/2009WO2009133127A1 Fused bicyclic compounds and use thereof as pi3k inhibitors
11/05/2009WO2009133103A1 Inhibitors of gm-csf and il-17 for therapy
11/05/2009WO2009133071A2 Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
11/05/2009WO2009132876A1 Cytotoxic immunoglobulin
11/05/2009WO2009132660A1 Agents binding to megalin or sex hormone binding globulin and compositions therof for treatment of steroid dependent cancers
11/05/2009WO2009132397A1 Methods and agents for modulating the level and/or activity of hif-2 alpha protein
11/05/2009WO2009113108A3 Styrene maleic anhydride based formulation for male contraception and prostate cancer
11/05/2009WO2009112245A9 Antibody against the csf-1 r
11/05/2009WO2009111846A4 Mitochondrially delivered anti-cancer compounds
11/05/2009WO2009105673A3 Tumor therapy with replication competent sindbis viral vectors
11/05/2009WO2009102497A3 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
11/05/2009WO2009102496A3 Selective agonist of toll-like receptor 3
11/05/2009WO2009099840A3 Methods of manufacture of morinda citrifolia based compositions for treatment of anti-inflammatory diseases through inhibition of cox-1, cox-2, interleukin-1beta, interleukin-6, tnf-alpha, hle, and inos
11/05/2009WO2009091898A3 6-and 7-amino isoquinoline compounds and methods for making and using the same
11/05/2009WO2009089453A9 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
11/05/2009WO2009071480A3 Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
11/05/2009WO2009070244A3 Methods for inhibiting fascin
11/05/2009WO2009066283A3 Calcium-mediated effects of coral and methods of use thereof
11/05/2009WO2009046879A3 Use of the combination of npy and nociceptin as a therapeutic agent
11/05/2009WO2009046876A3 Use of a peptide as a therapeutic agent
11/05/2009WO2009043526A3 Use of gip ( 6-30) alone or in combination with hgh as a therapeutic agent
11/05/2009WO2009040051A9 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent
11/05/2009WO2009040005A9 Use of the peptide rfmwmr as a therapeutic agent
11/05/2009WO2009033819A3 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
11/05/2009WO2009033797A3 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
11/05/2009WO2009033785A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
11/05/2009WO2009033784A3 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
11/05/2009WO2009033738A3 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
11/05/2009WO2009033712A3 Use of melanotan ii as a therapeutic agent
11/05/2009WO2009000971A3 Peptide gacfsiahecga for targeting mtl-mmp
11/05/2009WO2008154333A3 Mir-34 regulated genes and pathways as targets for therapeutic intervention
11/05/2009WO2008152508A3 Cytokine conjugate
11/05/2009WO2008134020A8 Ccl18 and ccl3 methods and compositions for detecting and treating cancer
11/05/2009WO2008127659A3 Anticancer combination of a dac inhibitor and a tyrosine kinase inhibitor
11/05/2009WO2008110379A8 Monoclonal antibodies for treatment of cancer
11/05/2009WO2008060705A8 Anti-dll4 antibodies and methods using same
11/05/2009US20090276863 Protein formulations comprising s1-5
11/05/2009US20090275664 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
11/05/2009US20090275656 Medicinal Compositions of Salts, Chelates and/or Free Acids of Alpha Hydroxyl Organic Acids and Related Processes and Methods
11/05/2009US20090275654 Pharmaceutical Gallium Compositions and Methods
11/05/2009US20090275650 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof
11/05/2009US20090275644 Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof
11/05/2009US20090275642 Dna composition for eliciting an immune response against tumor-associated macrophages
11/05/2009US20090275635 Screening method
11/05/2009US20090275624 Inhibitors of cdc phosphatases
11/05/2009US20090275623 Alpha-amino acid derivatives and medicaments containing the same as an active ingredient
11/05/2009US20090275619 Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
11/05/2009US20090275606 Heterocyclic Compounds as MEK Inhibitors
11/05/2009US20090275603 NF- kB Inhibitors And Uses Thereof
11/05/2009US20090275592 Heterocyclic modulators of PKB
11/05/2009US20090275586 Heterocyclic inhibitors of pde4
11/05/2009US20090275585 Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition
11/05/2009US20090275582 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases
11/05/2009US20090275576 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/05/2009US20090275575 Benzophenone derivatives useful for inhibiting formation of microtubule
11/05/2009US20090275570 Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
11/05/2009US20090275567 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation
11/05/2009US20090275564 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
11/05/2009US20090275549 Use of picoplatin to treat colorectal cancer
11/05/2009US20090275548 Compounds and methods for activated therapy
11/05/2009US20090275533 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
11/05/2009US20090275526 Mucoadhesive nanoparticles for cancer treatment
11/05/2009US20090275523 Spirocyclic nitriles as protease inhibitors
11/05/2009US20090275521 Regulation of Microphage Migration Inhibitory Factor (MIF) Activity
11/05/2009US20090275519 Therapeutic peptidomimetic macrocycles
11/05/2009US20090275516 Compounds and method for modulating inflammatory reactions
11/05/2009US20090275515 2-hydroxy-2-phenylthiophenylpropionamides as androgen receptor modulators
11/05/2009US20090275501 Somatostatin-dopamine chimeric analogs
11/05/2009US20090275041 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
11/05/2009US20090275024 Novel centrerosome-associated protein and applications thereof
11/05/2009US20090274773 Antiproliferative combination comprising cyc-682 and a cytotoxic agent
11/05/2009US20090274765 Compositions and Methods for Drug Delivery
11/05/2009US20090274751 Growth Factor Sensitive Vesicle
11/05/2009US20090274746 Methods and compositions for controlled delivery of phytochemical agents
11/05/2009US20090274713 Cross-linkers and their uses
11/05/2009US20090274712 Compositions for coating cell membranes and methods of use thereof
11/05/2009US20090274700 Il-31 receptor antibodies
11/05/2009US20090274699 Ul16 binding protein 4
11/05/2009US20090274698 Combination anti-cancer therapy
11/05/2009US20090274695 Inhibition of urokinase-type plasminogen activator (uPA) activity
11/05/2009US20090274693 Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor
11/05/2009US20090274692 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
11/05/2009US20090274691 Use of CD25 binding molecules in steroid-resistant patients
11/05/2009US20090274686 Nucleoside phosphonate derivatives
11/05/2009US20090274680 Human Phospholipases
1 ... 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 ... 2211